IntelliPharmaCeutics Intl Inc (USA)
(Public, NASDAQ:IPCI) Watch this stockFind more results for
VSGN
Advertisement
Key stats and ratios
| Q3 (Aug '09) | 2008 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -75.65% | -85.98% |
| Return on average equity | -89.28% | -67.20% |
| Employees | 6 | - |
Address
30 Worcester Road
Toronto, ON M9W 5X2
Canada
+1-905-5699065 (Phone)
+1-905-5699231 (Fax)
Toronto, ON M9W 5X2
Canada
+1-905-5699065 (Phone)
+1-905-5699231 (Fax)
Website links
Company website:
http://www.intellipharmaceutics.com...
http://www.intellipharmaceutics.com...
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
IntelliPharmaCeutics Intl Inc (USA) discussions
View all discussions »Description
IntelliPharmaCeutics International Inc. is a pharmaceutical development company specializing in the controlled and targeted once-a-day delivery of oral, solid dose pharmaceutical products. The company develops drugs using its drug delivery platform namely HYPERMATRIX. This technology works relating to the human body, responding to the multivariate external environment of the Gastro-Intestinal Tract (GIT). On October 22, 2009, Vascogen Inc combined with Intellipharmaceutics Ltd. in a plan of arrangement and merger to become the new company, Intellipharmaceutics International Inc.
Officers and directors
| Isa Odidi Ph.D. | Chairman of the Board, Chief Executive Officer | |
| Amina Odidi Ph.D. | President, Chief Operating Officer, Director | |
| John N. Allport | Vice President - Legal Affairs and Licensing, Director | |
| Patrick N. Yat Ph.D. | Vice President - Pharmaceutical Analysis and Chemistry | |
| Eldon R. Smith M.D. | Director | |
| Bahadur Madhani | Director | |
| Kenneth Keirstead | Director |